PARP1 and ovarian carcinoma: After the first promising clinical trials using a Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) as treatments for platinum-sensitive BRCA1/2 mutated breast and ovarian cancers, several PARP inhibitors have been approved by the FDA/EMA as monotherapies or combination therapies for BRCA mutated and/or platinum-sensitive breast and ovarian tumors (1, 2).